Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
2023-04-27 10:16:50 ET Daiichi Sankyo Co. ( OTCPK:DSKYF ): FY GAAP EPS of ¥56.91. Revenue of ¥1.28T. For further details see: Daiichi Sankyo Co. GAAP EPS of ¥56.91, revenue of ¥1.28T
2023-04-21 11:32:43 ET The US FDA has extended by three months its review of Daiichi Sankyo's ( OTCPK:DSKYF ) NDA for quizartinib for newly diagnosed acute myeloid leukemia (AML). The new agency action date is July 24. The reason for the extra time is that the agency needs...
2023-04-20 12:12:30 ET Summary BMEZ launched right before Covid, riding up the boost when speculative growth took off. In 2022, the story was much different, and the fund struggled significantly. This fund is much riskier than its older sister fund, BME, but it also can provid...
2023-03-16 09:07:22 ET Esperion Therapeutics ( NASDAQ: ESPR ) continued the post-market selloff on Thursday due to a payment dispute with Daiichi Sankyo ( OTCPK:DSNKY ) over its cholesterol-lowering agent bempedoic acid, prompting Bank of America to downgrade the stock. ...
Summary Viatris' gross margin reached its highest level since its inception in the fourth quarter of 2020, despite rising raw material and labor costs. On February 27, 2023, Viatris management will publish financial results for the 4th quarter of 2022. Viatris' operating income for ...
Daiichi Sankyo press release ( OTCPK:DSKYF ): 9M GAAP EPS of ¥45.19. Revenue of ¥948.28B (+16.9% Y/Y). For further details see: Daiichi Sankyo GAAP EPS of ¥45.19, revenue of ¥948.28B
Summary As a leader in various therapeutic areas, the company's total revenue was $7,042 million in the third quarter of 2022, up 12.5% quarter-on-quarter. Gilead will be required to make royalties of 3% on future sales of Biktarvy and bictegravir-containing medicines up to the 4th quar...
Daiichi Sankyo ( OTCPK:DSKYF ) ( OTCPK:DSNKY ) submitted an application to the regulatory authorities in Japan seeking approval of its mRNA COVID-19 vaccine DS-5670 as a booster shot. The Japanese drugmaker said the application was backed by data from a phase 1/2/3 tri...
Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...
Summary FDA and EU approved, the joint therapy Enhertu is set to become a blockbuster. The therapy targets HER-2 cancers and is already expanding indications beyond breast cancer. With this successful antibody-drug conjugate, the entire sub-industry is now seeing renewed momentum he...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...